FIELD: biotechnology; medicine.
SUBSTANCE: invention relates to the field of biotechnology and medicine. The present invention discloses a botulinum neurotoxin (BoNT) polypeptide with a modified receptor binding domain (HC) having one or more amino acid mutations that modify BoNT binding to the receptor. Specific mutations and combinations of mutations are also described. Also disclosed are isolated modified nucleic acids, chimeric molecules, pharmaceutical compositions and methods for their preparation and use.
EFFECT: invention relates to one of the promising directions in the development of new methods of treatment of a number of diseases.
20 cl, 3 tbl, 1 ex, 21 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| CONSTRUCTED BOTULINUM NEUROTOXIN | 2017 |
|
RU2789302C2 |
| BOTULINUM NEUROTOXIN BIOHYBRID | 2019 |
|
RU2816855C2 |
| METHODS FOR PRODUCING PROTEOLYTICALLY PROCESSED POLYPEPTIDES | 2018 |
|
RU2719164C1 |
| HYBRID NEUROTOXINS | 2017 |
|
RU2782382C2 |
| METHODS FOR PRODUCING PROTEOLYTICALLY PROCESSED POLYPEPTIDES | 2019 |
|
RU2727402C1 |
| THERAPEUTIC AND COSMETIC USE OF SEROTYPE E NEUROTOXIN BOTULINUM | 2019 |
|
RU2800604C2 |
| ANTIBODIES AGAINST STAPHYLOCOCCUS AUREUS LEUKOTOXINS | 2019 |
|
RU2805969C2 |
| COMBINATIONS OF ANTIBODIES TO STAPHYLOCOCCUS AUREUS | 2019 |
|
RU2804815C2 |
| ANTIBODIES AGAINST ANGPTL3/8 COMPLEX AND THEIR APPLICATION METHODS | 2019 |
|
RU2791034C2 |
| ANTIGENIC POLYPEPTIDES BASED ON OSPA SEQUENCE | 2019 |
|
RU2816208C2 |
